Abstract

Low-Concentration Samples: The Next Diagnostic Frontier

Richard Spero, CEO, Redbud Labs

New platforms for molecular analysis have ushered in a golden era of biomarker discovery and diagnostic development. Looking ahead, the greatest diagnostic challenges have a common thread: the analyte is present in extremely low concentration. We discuss novel methods for improving limit of detection in analyte-limited samples.